Publications by authors named "J Begun"

Background/aims: Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population.

View Article and Find Full Text PDF

The lack of clear definition and classification for "moderate ulcerative colitis (UC)" creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC.

View Article and Find Full Text PDF

Background: Diagnostic imaging using CT enterography, magnetic resonance enterography, and intestinal ultrasound are important tools in evaluating stricturing Crohn's disease. Definitions of strictures have been developed for CT enterography and magnetic resonance enterography. However, expert recommendations for definitions and treatment response of strictures on intestinal ultrasound are not available.

View Article and Find Full Text PDF
Article Synopsis
  • Group B Streptococcus (GBS) can asymptomatically colonize the vagina of up to 40% of pregnant women, posing risks for serious infections in newborns during delivery.
  • A study analyzed vaginal samples from 93 pregnant women to explore the relationship between vaginal microbial community composition and GBS colonization at 24 and 36 weeks of gestation.
  • Findings indicated that women persistently colonized with GBS showed a significant increase in specific bacterial abundance while experiencing a decrease in others, highlighting the need for further research on how these microbial communities interact with GBS during pregnancy.
View Article and Find Full Text PDF

Background: Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative colitis (UC) and Crohn's disease (CD).

View Article and Find Full Text PDF